Riluzole use and reasons for non-use in people with amyotrophic lateral sclerosis in Aotearoa New Zealand
New Zealand Medical Journal · 2026
DOI: 10.26635/6965.7238 ↗Kurz gefasst
Fachartikel in der Zeitschrift New Zealand Medical Journal, 2026. Verfasst von Natalie Gauld und 5 weiteren Autor:innen. Beteiligte Einrichtung: Honorary Senior Clinical Lecturer, School of Pharmacy, The University of Auckland, Auckland; Research Advisor and Best Practice Advocate, Motor Neuro…. Hauptthemen laut MEDLINE: Riluzole, Amyotrophic Lateral Sclerosis, Neuroprotective Agents. Gefördert von: This research was funded by a Health Research Council Research Activation Grant, a Motor Neurone Disease New Zealand grant and some voluntary time by the autho….
Abstract (Originalsprache)
Amyotrophic lateral sclerosis (ALS), the most common form of motor neurone disease (MND), is a neurodegenerative condition with typically short life expectancy. Riluzole, the only survival-prolonging medication funded in Aotearoa New Zealand, has high uptake in other developed countries. aims: To quantify riluzole use in New Zealand, identify factors associated with its use and explore reasons for non-use. methods: In 2025, people in New Zealand diagnosed with MND were invited to self-complete questionnaires. Data were collected via Qualtrics, exported to Excel and analysed using descriptive and inferential statistics. Respondents with progressive muscular atrophy or primary lateral sclerosis diagnoses were excluded from this analysis. results: Of 115 respondents, 55 (48%) were currently taking riluzole, 14 (12%) had taken it previously and 42 (36%) had never taken it. Common reasons for non-use included riluzole not being offered and concerns about lack of effectiveness and/or side effects. Uptake was lower with bulbar onset than limb onset (p
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Substanzen
Autor:innen und Institutionen
- Honorary Senior Clinical Lecturer, School of Pharmacy, The University of Auckland, Auckland; Research Advisor and Best Practice Advocate, Motor Neurone Disease New Zealand, Auckland.
- Neurologist Tauranga Hospital, Tauranga; Honorary Senior Lecturer, The University of Auckland, Auckland; Medical Adviser Motor Neurone Disease New Zealand, Auckland.
- Neurologist, Dunedin Hospital, Dunedin; Senior Lecturer, Dunedin School of Medicine, University of Otago, Dunedin.
- Senior Lecturer, Te Kupenga Hauora Māori, The University of Auckland, Auckland, New Zealand.
- Professor, Department of Medicine, University of Otago, Christchurch, New Zealand.
- Associate Professor, Department of General Practice, The University of Auckland, Auckland.
Förderung
- This research was funded by a Health Research Council Research Activation Grant, a Motor Neurone Disease New Zealand grant and some voluntary time by the autho…
Zitieren
APA
Gauld, N., Cleland, J., Buchanan, S., Hikaka, J., Frampton, C., & Buetow, S. (2026). Riluzole use and reasons for non-use in people with amyotrophic lateral sclerosis in Aotearoa New Zealand. New Zealand Medical Journal. https://doi.org/10.26635/6965.7238
Vancouver
Gauld N, Cleland J, Buchanan S, Hikaka J, Frampton C, Buetow S. Riluzole use and reasons for non-use in people with amyotrophic lateral sclerosis in Aotearoa New Zealand. New Zealand Medical Journal. 2026. doi:10.26635/6965.7238
BibTeX
@article{Gauld2026,
author = {Gauld, Natalie and Cleland, James and Buchanan, Sarah and Hikaka, Joanna and Frampton, Chris and Buetow, Stephen},
title = {Riluzole use and reasons for non-use in people with amyotrophic lateral sclerosis in Aotearoa New Zealand},
journal = {New Zealand Medical Journal},
year = {2026},
doi = {10.26635/6965.7238}
}
EUVIMED